This is a working overview of lipolysis, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2026-08-01 and is reviewed periodically as new material appears.
AOD-9604 is a synthetic peptide whose sequence is modeled on the C-terminal region of human growth hormone. Published descriptions commonly place it as a modified fragment corresponding to hGH amino acids 176–191, with a tyrosine residue added or retained at the N-terminus to support detection and handling. It is not intact growth hormone and lacks the full receptor-binding architecture of the parent protein. The molecule was developed as a research candidate for metabolic studies rather than as a replacement for growth hormone therapy. Its identity is defined by its amino acid sequence rather than by any single commercial preparation.
AOD-9604 drew attention in the 1990s and 2000s as a potential anti-obesity agent. Early work explored both injectable and oral routes, which is unusual for a peptide of this size. Animal studies reported changes in fat metabolism without the growth-promoting or insulin-like effects associated with full-length growth hormone. Subsequent human trials produced mixed or modest results, and the compound did not obtain regulatory approval for weight management in major markets. It remains known mainly through research literature, sports anti-doping listings, and non-approved supplement advertising.
Regulatory treatment of AOD-9604 has varied. In sports anti-doping, the peptide became widely discussed during a 2013 investigation into an Australian professional sports club. Authorities at the time debated whether it fell under prohibitions on growth hormone and related substances. Later clarifications and updated lists have addressed the compound in different ways. Anyone seeking current status should consult the latest applicable rules, and commercial supply for human use is not authorized in major markets.
Research interest in AOD-9604 often focuses on whether it can influence lipid metabolism without the growth-promoting or glucose-related effects of full-length hGH. This question remains unresolved, and findings depend on model, dose, and measurement method. Some reviews treat the peptide as a historical obesity candidate rather than an active therapeutic. Others cite it in discussions of peptide fragments, metabolic signaling, and performance-enhancing substances. Clear conclusions are limited by the small number of rigorous, independent human studies.
AOD-9604 has been investigated primarily as a potential treatment for obesity and related metabolic conditions. Early laboratory work examined its effects on fat cells, and later studies moved into animal models and human clinical trials. Some trials reportedly reached Phase II, but the program did not lead to an approved medicine. Published summaries often note that weight-loss results were modest or inconsistent. The full trial data are not all publicly available in detail.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Fragment analog of human growth hormone |
| Sequence basis | hGH 176–191 region | Modified C-terminal fragment |
| Common synonyms | AOD-9604; AOD9604; hGH fragment | Research and trade names vary |
| Regulatory status | Not approved as a drug | Prohibited in competitive sport |
| Research code | AOD9604 | Used in scientific and patent literature |
AOD9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to a short sequence near the end of the 191-amino-acid hormone, often described as residues 176–191 or a related fragment. Researchers designed it to separate metabolic effects from the growth-promoting actions of full-length growth hormone. Early work in the 1990s explored it as a candidate for weight and lipid disorders. It is not a naturally circulating hormone fragment produced in large amounts.
Laboratory studies have reported that AOD9604 can increase lipolysis and reduce lipid accumulation in fat cells. The precise molecular target remains uncertain, and the compound does not appear to activate the growth hormone receptor in the same way as full-length hGH. Proposed mechanisms include effects on beta-adrenergic signaling and enzymes involved in fatty acid synthesis, but these pathways are not firmly established. Because most evidence comes from cell and animal models, whether the same effects occur in humans is an open question.
Clinical development of AOD9604 included trials in people with obesity, but the results did not lead to approval as a prescription medicine in major markets. Interest later shifted to research settings and to unapproved products marketed for body composition. Regulatory agencies have questioned whether the peptide qualifies as a dietary ingredient, and some have issued warnings about its presence in supplements. Long-term human safety data are limited, and questions about efficacy, dosing, and target populations remain unresolved.
Analytical characterization of AOD-9604 typically employs reversed-phase high-performance liquid chromatography (RP-HPLC) to assess purity and identity. Mass spectrometry provides confirmation of molecular mass, while amino acid analysis can verify composition. These methods are standard for peptide research chemicals. Because the peptide lacks a distinct chromophore, detection often relies on ultraviolet absorbance at 214 nm or mass spectrometric response. Laboratories may also use capillary electrophoresis for separation. For example, size-exclusion chromatography can detect aggregates.
Stability of AOD-9604 depends on storage conditions. Lyophilized powder is generally more stable than reconstituted solution. Recommended storage is typically at -20°C or lower, protected from light and moisture. Repeated freeze-thaw cycles can cause aggregation or degradation. In solution, the peptide may be susceptible to hydrolysis or oxidation, so aliquoting and cold storage are common practices. Researchers often add stabilizers such as mannitol or trehalose during lyophilization to improve shelf life.
Quality control for AOD-9604 involves verifying identity, purity, and concentration. Suppliers may provide a certificate of analysis listing HPLC purity and mass spectrometry data. Independent verification is advised because peptide products can vary in quality. Researchers should check for counterions, residual solvents, and microbial contamination. Proper documentation supports reproducibility and safety in laboratory studies. When sourcing, institutions often require third-party testing and detailed chain-of-custody records. These steps help ensure that experimental results are attributable to the peptide rather than impurities.
Regulatory bodies have taken different approaches to AOD-9604. It is not approved as a prescription medicine by major agencies such as the U.S. Food and Drug Administration or the European Medicines Agency. In sport, the World Anti-Doping Agency prohibits peptide hormones, growth factors, and related substances, and AOD-9604 has been treated as a prohibited substance. These regulatory decisions reflect concerns about safety, efficacy, and potential misuse rather than proof of benefit.
Research on AOD-9604 also examines how the peptide is measured in biological samples. Analytical methods may include liquid chromatography coupled with mass spectrometry, immunoassays, or both. Detection can be challenging because the peptide is small and may be present at low concentrations. Published methods vary in sensitivity and specificity, so comparative interpretation requires attention to validation details. The presence of related hGH fragments can complicate identification in some matrices.
Regulatory treatment of AOD-9604 is shaped by its classification as a peptide hormone. The World Anti-Doping Agency lists it as a prohibited substance, and many national anti-doping organizations adopt that list. It does not hold approval as a prescription medicine in the United States, the European Union, or other major markets. Products sold online are frequently labeled for research use only and may not undergo independent quality testing. Import and possession rules differ by country, so legal status depends on local law.
Proposed mechanisms for AOD-9604 focus on fat cells. Laboratory studies suggest the peptide can increase lipolysis, the breakdown of stored fat, and reduce lipogenesis, the formation of new fat. Unlike full human growth hormone, it does not appear to stimulate substantial IGF-1 production in the studies reported so far. Some evidence points to beta-adrenergic signaling, but the precise receptor targets and downstream pathways remain unresolved. The fragment is not thought to act through the classical growth hormone receptor.
Clinical development of AOD-9604 included trials in people with obesity. Reports from early-phase and mid-phase studies described modest or inconsistent changes in body weight. A phase IIb program did not meet its primary endpoint, and the compound was not approved for medical use. Differences in formulation, delivery route, and participant characteristics may explain some of the variation. Later investigations explored whether the peptide might have effects in other tissues, including cartilage.
Another former Sport Dynamo athlete, Ilona Slupianek, was disqualified for doping. (Ilona Slupianek failed a test along with three Finnish athletes at the 1977 European Cup, becoming the only East German athlete ever to be convicted of doping) Based on the admission by Pollack, the United States Olympic Committee asked for the redistribution of gold medals won in the 1976 Summer Olympics. Despite court rulings in Germany that substantiate claims of systematic doping by some East German swimmers, the IOC executive board announced that it has no intention of revising the Olympic record books. In rejecting the American petition on behalf of its women's medley relay team in Montreal and a similar petition from the British Olympic Association on behalf of Sharron Davies, the IOC made it clear that it wanted to discourage any such appeals in the future.
=== Nonsense === Nonsense mutations are changes in DNA sequence that introduce a premature stop codon, causing any resulting protein to be abnormally shortened. This often causes a loss of function in the protein, as critical parts of the amino acid chain are no longer assembled. Because of this terminology, stop codons have also been referred to as nonsense codons.
Silver salts have antiseptic properties. In 1881 Credé introduced a method known as Credé's prophylaxis, which used of dilute (2%) solutions of silver nitrate in newborn babies' eyes at birth to prevent contraction of gonorrhea from the mother, which could cause blindness via ophthalmia neonatorum. (Modern antibiotics are now used instead). Fused silver nitrate, shaped into sticks, was traditionally called "lunar caustic". It is used as a cauterizing agent, for example to remove granulation tissue around a stoma. General Sir James Abbott noted in his journals that in India in 1827 it was infused by a British surgeon into wounds in his arm resulting from the bite of a mad dog to cauterize the wounds and prevent the onset of rabies. Silver nitrate is used to cauterize superficial blood vessels in the nose to help prevent nosebleeds. Dentists sometimes use silver nitrate-infused swabs to heal oral ulcers. Silver nitrate is used by some podiatrists to kill cells located in the nail bed. The Canadian physician C. A. Douglas Ringrose researched the use of silver nitrate for sterilization procedures, believing that silver nitrate could be used to block and corrode the fallopian tubes. The technique was ineffective.
Pancreatic polypeptide (PP) is a polypeptide secreted by PP cells in the endocrine pancreas. It is a hormone and it regulates pancreatic secretion activities, and also impacts liver glycogen storage and gastrointestinal secretion. Its secretion may be impacted by certain endocrine tumours.
Sources: en.wikipedia.org
== Mass spectrometry == Mass spectrometry is commonly used to identify the sugar moieties attached, but since there are many different glycan structures attached and different locations of glycosylation, this leads to challenges when attempting to sequence glycoproteins. Using mass spectrometry, there are two methods for glycoprotein analysis. The first strategy is called "top-down" which uses intact glycoproteins for the mass spectrometry analysis without digesting and does not require an extensive sample preparation. The second and most common method for studying glycoproteins is the "bottom-up" strategy that initially cleaves the glycans from the glycoproteins using chemicals or enzymes. The glycans, which are carbohydrates, and proteins are purified, and individually analyzed. Based on the type of linkage that these glycans use to attach to proteins, different methods are used to separate the glycan from the protein. Using mass spectrometry, the glycan structures and sequences of the proteins can be determined, but where the glycans bind to on the protein is sometimes undetermined. The last approach involves glycoprotein digestion using the enzyme, endoprotease, so the digested glycoproteins can then be characterized by mass spectrometry techniques. Using this method, the glycosylated sites can be identified, so these approaches are used in conjunction when trying to identify glycoproteins. As technology progresses, glycoprotein analyses have become more accurate using high-resolution mass spectrometry instrumentations.
Oral fluphenazine rapidly absorbs and plasma levels peak at about 1.0-2.5 ng/mL 2 hours post-ingestion. The volume of distribution is about 298 L due to extensive tissue uptake, and it crosses the blood brain barrier. Bioavailability is low at 2.7% due to first pass metabolism, and the half-life is about 14–16 hours. Steady state concentrations vary considerably across individuals, which indicates variability in absorption, metabolism, or excretion. Additionally, the dose-level relationship is curvilinear with plasma levels of 0.2 - 2.8 ng/mL being optimal for clinical improvement. Fluphenazine is primarily metabolized to fluphenazine sulfoxide by the cytochrome P450 2D6. Benztropine mesylate did not indicate any major drug-drug interactions. Fluphenazine is exreted primarily through urine and feces. Injectable fluphenazine is dissolved in sesame oil which forms a localized oil depot in the muscle. Due to the lipophilicity of the added decanoate or enanthate group, the drug remains in the oil causing the rate-limiting step for drug being diffusion out, resulting in flip-flop kinetics. Fluphenazine decanoate and enanthate are prodrugs which are hydrolyzed by esterases to fluphenazine. The fluphenazine decanoate acts within 1–3 days, and its effect lasts an average of 2 weeks. The half-life of fluphenazine decanoate is about 6.8-9.6 days, and plasma levels peak at about 2.18 ng/mL about 4–6 hours post injection. Fluphenazine enanthate has a lower half life of about 3.6-3.7 days, reflecting its decreased lipophilicity.
89Sr is the active ingredient in Metastron, a radiopharmaceutical used for bone pain secondary to metastatic bone cancer. The strontium is processed like calcium by the body, preferentially incorporating it into bone at sites of increased osteogenesis. This localization focuses the radiation exposure on the cancerous lesion. 90Sr has been used as a power source for radioisotope thermoelectric generators (RTGs). 90Sr produces approximately 0.93 watts of heat per gram (it is lower for the form of 90Sr used in RTGs, which is strontium fluoride). However, 90Sr has one third the lifetime and a lower density than 238Pu, another RTG fuel. The main advantage of 90Sr is that it is significantly cheaper than 238Pu and is found in nuclear waste. The latter must be prepared by irradiating 237Np with neutrons then separating the modest amounts of 238Pu. The principal disadvantage of 90Sr is the high energy beta particles produce Bremsstrahlung as they encounter nuclei of other nearby heavy atoms such as adjacent strontium. This is mostly in the range of X-rays. Thus strong beta emitters also emit significant secondary X-rays in most cases. This requires significant shielding measures which complicates the design of RTGs using 90Sr. The Soviet Union deployed nearly 1000 of these RTGs on its northern coast as a power source for lighthouses and meteorology stations.
Sources: en.wikipedia.org
No. It is a synthetic peptide fragment modeled on part of human growth hormone, not the full hormone. It does not contain the complete sequence or receptor-binding regions of hGH.
It was investigated in clinical trials for obesity, but it did not receive approval for that use in major markets. Results were generally modest or mixed, and it remains an experimental compound.
WADA lists it as a prohibited peptide hormone. Its use can be detected by laboratory methods, and athletes are subject to sanctions if it is found in samples.
No major medicines regulator appears to have approved AOD-9604 for human therapeutic use. It has been studied in clinical trials, but those programs did not result in a marketed drug.